journal article·2026-04Open access

HSP90AB1‐Mediated Ubiquitin‐Proteasome Degradation of ITGBL1 Promotes Osteosarcoma Progression by Inhibiting Endoplasmic Reticulum Stress‐Induced Autophagy

Zhen Wang, Zixuan Guo, Chengwei Cao, Ziying Wang, Zifu Huang, Xiujuan Zhang, Yushu Zheng, Diankun She, Hao Zhu, Lingfeng Yu, Xuelin Zhao, Dongquan Xiang, Song Liao, Xin He, Xintong Ji, Chengsheng Wu, Cheng‐Xiong Xu, Meng Xu

Advanced Science· Volume 13· Issue 23

Abstract

ABSTRACT Osteosarcoma (OS) is one of the most malignant bone tumors in children and adolescents, but the molecular mechanisms of OS progression remain largely undefined. In this study, we demonstrate that Integrin subunit beta‐like 1 (ITGBL1) is downregulated in OS tissues, and its downregulation correlates with poor prognosis in OS patients. Functional assays revealed that ITGBL1 inhibits OS cell growth, metastasis, and stemness, while promoting apoptosis. The in vitro and in vivo experiments further revealed that ITGBL1 activates endoplasmic reticulum (ER) stress by upregulating ROS, thereby triggering autophagy in OS cells. In addition, the downregulation of ITGBL1 in OS is partly attributed to the abnormal upregulation of HSP90AB1 (heat shock protein 90 alpha family class B1). Mechanistically, ITGBL1 interacts with HSP90AB1 which facilitates ITGBL1 degradation through K63‐linked ubiquitination. Finally, through virtual screening and Co‐IP, we identified ivermectin as a potent inhibitor of the HSP90AB1‐ITGBL1 interaction, and treatment with ivermectin dramatically inhibited OS progression in vivo. In conclusion, we uncover a novel mechanism that promotes OS progression and identify a new candidate drug for the treatment of OS.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Heat shock proteins research · Ubiquitin and proteasome pathways · Autophagy in Disease and Therapy

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Medical School of Chinese PLA Beijing China

Senior Department of Orthopedics the Fourth Medical Centre Chinese PLA General Hospital Beijing China

Department of Cell Engineering Beijing Institute of Biotechnology Beijing China

Department of Orthopedics Jinling Hospital Affiliated Hospital of Medical School Nanjing University Nanjing Jiangsu China

Institute of Basic Medical Sciences Chinese Academy of Medical Sciences School of Basic Medicine Peking Union Medical College Beijing China

Department of Orthopedic Oncology Shanghai Bone Tumor Institute Shanghai General Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

College of Life Sciences University of Chinese Academy of Sciences Beijing China

School of Medicine Chongqing University Chongqing China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (62)

Show source-provided references
1. 10.1038/s41572‐022‐00409‐y10.1038/s41572‐022‐00409‐y ↗
2. 10.1200/JCO.2014.59.489510.1200/JCO.2014.59.4895 ↗
3. 10.1056/NEJMra210342310.1056/NEJMra2103423 ↗
4. 10.1006/geno.1998.570710.1006/geno.1998.5707 ↗
5. 10.1158/0008‐5472.CAN‐15‐024010.1158/0008‐5472.CAN‐15‐0240 ↗
6. 10.1111/cpr.1283610.1111/cpr.12836 ↗
7. 10.1038/s41467‐020‐14869‐x10.1038/s41467‐020‐14869‐x ↗
8. 10.7150/jca.2090010.7150/jca.20900 ↗
9. 10.1016/j.biopha.2016.03.05310.1016/j.biopha.2016.03.053 ↗
10. 10.1007/s13277‐015‐3919‐810.1007/s13277‐015‐3919‐8 ↗
11. 10.1016/j.gene.2015.08.06310.1016/j.gene.2015.08.063 ↗
12. 10.3389/fonc.2015.0010010.3389/fonc.2015.00100 ↗
13. 10.1038/nrc171610.1038/nrc1716 ↗
14. 10.1038/s41388‐018‐0532‐510.1038/s41388‐018‐0532‐5 ↗
15. 10.1038/s41416-020-01250-410.1038/s41416-020-01250-4 ↗
16. 10.3389/fimmu.2024.144555510.3389/fimmu.2024.1445555 ↗
17. 10.1038/s41580‐024‐00794‐010.1038/s41580‐024‐00794‐0 ↗
18. 10.1146/annurev‐pathol‐012513‐10464910.1146/annurev‐pathol‐012513‐104649 ↗
19. 10.1038/s41581‐025‐00938‐110.1038/s41581‐025‐00938‐1 ↗
20. 10.1126/science.120903810.1126/science.1209038 ↗
21. 10.1038/s41568‐020‐00312‐210.1038/s41568‐020‐00312‐2 ↗
22. 10.1038/s41580‐020‐0241‐010.1038/s41580‐020‐0241‐0 ↗
23. 10.4161/auto.5.8.1016810.4161/auto.5.8.10168 ↗
24. 10.1016/j.jconrel.2018.02.01010.1016/j.jconrel.2018.02.010 ↗
25. 10.1002/ar.2264110.1002/ar.22641 ↗
26. 10.1002/advs.20241255310.1002/advs.202412553 ↗
27. 10.1038/s12276‐025‐01582‐210.1038/s12276‐025‐01582‐2 ↗
28. 10.1038/s41467‐025‐64066‐x10.1038/s41467‐025‐64066‐x ↗
29. 10.1002/advs.20240831110.1002/advs.202408311 ↗
30. Measuring Autophagosome Flux
31. 10.1126/sciadv.adt768210.1126/sciadv.adt7682 ↗
32. 10.1186/2162‐3619‐2‐1710.1186/2162‐3619‐2‐17 ↗
33. 10.1016/j.apsb.2021.07.01210.1016/j.apsb.2021.07.012 ↗
34. 10.1038/s41419‐022‐05341‐310.1038/s41419‐022‐05341‐3 ↗
35. 10.1186/s12964-025-02198-910.1186/s12964-025-02198-9 ↗
36. 10.1016/j.freeradbiomed.2025.04.00910.1016/j.freeradbiomed.2025.04.009 ↗
37. 10.1038/s41420‐025‐02862‐610.1038/s41420‐025‐02862‐6 ↗
38. 10.1007/s11427‐023‐2737‐210.1007/s11427‐023‐2737‐2 ↗
39. 10.1016/j.intimp.2023.11104010.1016/j.intimp.2023.111040 ↗
40. 10.7150/thno.5877910.7150/thno.58779 ↗
41. 10.1016/j.bbrc.2011.08.13610.1016/j.bbrc.2011.08.136 ↗
42. 10.1186/s12935‐023‐03047‐w10.1186/s12935‐023‐03047‐w ↗
43. 10.1186/s12958‐018‐0404‐410.1186/s12958‐018‐0404‐4 ↗
44. 10.1021/ci300127710.1021/ci3001277 ↗
45. 10.1111/jcmm.1811310.1111/jcmm.18113 ↗
46. 10.2147/OTT.S20008210.2147/OTT.S200082 ↗
47. 10.1186/s13045‐021‐01192‐110.1186/s13045‐021‐01192‐1 ↗
48. 10.1016/j.bbamcr.2024.11986910.1016/j.bbamcr.2024.119869 ↗
49. 10.1016/j.phrs.2024.10735510.1016/j.phrs.2024.107355 ↗
50. 10.1186/s12931‐025‐03280‐z10.1186/s12931‐025‐03280‐z ↗
51. W.Peng D.Shi D.Xu et al. “Identification of Bruceine A as a Novel HSP90AB1 Inhibitor for Suppressing Hepatocellular Carcinoma Growth ” Journal of Advanced Research (forthcoming).
52. 10.1016/j.bioorg.2025.10878210.1016/j.bioorg.2025.108782 ↗
53. 10.1002/mco2.47010.1002/mco2.470 ↗
54. 10.1208/s12248‐007‐9000‐910.1208/s12248‐007‐9000‐9 ↗
55. 10.7150/ijms.7662310.7150/ijms.76623 ↗
56. 10.1172/JCI13081910.1172/JCI130819 ↗
57. 10.3389/fphar.2022.93474610.3389/fphar.2022.934746 ↗
58. Ivermectin as an Inhibitor of Cancer Stem‐Like Cells
59. 10.1016/j.phrs.2020.10520710.1016/j.phrs.2020.105207 ↗
60. 10.3389/fonc.2024.145695910.3389/fonc.2024.1456959 ↗
61. ARROW: Pralsetinib Hits Target Across Cancers
62. 10.1016/j.canlet.2025.21812110.1016/j.canlet.2025.218121 ↗